In cases of resistance or suboptimal response, as indicatedby persistent high BCR-ABL levels or hematologic abnormalities such as neutropenia and thrombocytopenia, treatment was escalated tosecond-generation TKIs like Nilotinib or Dasatinib. The gene discussed is ABL1; the disease is neutropenia.